This brand name is authorized in Estonia, Malta
The drug RELEFACT contains one active pharmaceutical ingredient (API):
|
1
Gonadorelin
UNII 9O7312W37G - GONADORELIN
|
|
Gonadorelin stimulates the synthesis of follicle stimulating hormone and luteinising hormone in the anterior lobe of the pituitary as well as their release. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H01CA01 | Gonadorelin | H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CA Gonadotropin-releasing hormones |
| V04CM01 | Gonadorelin | V Various → V04 Diagnostic agents → V04C Other diagnostic agents → V04CM Tests for fertility disturbances |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1375927 |
| Country: MT | Medicines Authority | Identifier(s): AA565/62301 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
